Organ-on-Chip Market

Global Organ-on-Chip Market Size (2024 to 2029)

The global organ-on-chip-market size is forecasted to be worth USD 532.63 million by 2029 from USD 112.23 million in 2024, registering a CAGR of 36.4% from 2024 to 2029.

An organ-on-a-chip (OOC) is a microfluidic cell culture device made with microchip manufacturing technologies that contain continuously perfused compartments populated by living cells and structured to mimic tissue and organ physiology. This chip creates a small channel for blood and air movement in organs like the lung, gut, liver, heart, and others. Using traditional 2D and 3D culture systems, such devices can develop different tissue and organ functionality levels. Organ-on-chip technology can be used for various purposes, including disease modeling, patient stratification, and phenotypic screening. Organs-on-chips, which simulate the physiology of human organs at the cellular level, is a viable alternative to animal models.

Global Organ-on-Chip Market Drivers:

Technological advancements and new product launches, a growing number of partnerships, and collaborations between pharmaceutical companies and organ-on-chips manufacturers are primarily promoting the global organ-on-chip market’s growth. Researchers and scientists use Organ-on-chip culture systems to test the effects of various medications on the human body. Furthermore, this technology is used to analyze drug toxicity or effectiveness in various organs. The growing number of these processes is predicted to support the global organ-on-chip market. The ever-increasing focus on developing alternatives to animal testing models, a significant increase in research funding, and venture capital investments for the development of organs-on-chips are anticipated to boost the growth rate of the global organ-on-chip market. In addition, a growing need for early detection of drug toxicity to minimize financial risks is another significant factor driving the growth of this market.

Furthermore, with the healthcare sector increasing demand for advanced organ-on-chip technologies, it's expected that the market will continue to grow rapidly in the future years. Organ-on-chip technologies are primarily utilized for in-vitro biochemical analysis, real-time imaging, and metabolic and genetic activities of living cells in functional tissue. The continually expanding application breadth of OOCs is projected to drive demand for organs on chips during the forecast period. The growing prevalence of cardiovascular diseases (CVD) is likely to propel the organ-on-a-chip market to new heights. Organ-on-a-chip technologies were created to simulate the dynamic conditions of the circulatory system, particularly the heart and the general vasculature. Personalized medicine is a developing area that allows physicians to construct a targeted treatment for their patients, i.e., choosing the best possible medicines at the optimal dose depending on their specific needs. It has a massive opportunity for improving patient outcomes, especially in areas where a thorough grasp of each person's phenotypic and disease profile is critical. These patient-specific models aid in the prediction of toxicity and efficacy. Patients will be paired with the most appropriate medicines that will work for them in the future due to an emphasis on early disease identification and personalized medicine.

Global Organ-on-Chip Market Restraints:

High production costs, as the costly redesigning process may be too much for the relatively tiny enterprises involved, may curb organ-on-chip market growth. Furthermore, developing bioreactors, and pumps for the perfusion of cell culture media, maintaining the cell environment, and mechanical stimuli, and implementing cell analysis methods are difficult and expensive. Manufacturers of organs-on-chips are increasingly turning to big data to deal with the data created by OOCs. The data generated by OOCs can face several challenges, including sharing, integrating, and evaluating it. In addition, big data methods must be implemented on modern high-performance computing platforms to use the created data properly.

Impact of COVID-19 on the global organ-on-chip market:

Since the COVID-19 outbreak, the biopharmaceutical industry and the scientific community have become exceedingly proactive. As a result, Organ-on-chip has become one of the most adaptable technologies for generating medications and vaccines amid the pandemic. Simply put, the novel coronavirus has emerged as a profitable opportunity for the organ-on-a-chip sector, with constant growth expected during the forecast period.

REPORT COVERAGE:

This research report on the global organ-on-chip market has been segmented and sub-segmented based on type, application, and region.

Global Organ-on-chip Market – By Type:

• Heart-on-chip
• Human-on-chip
• Intestine-on-chip
• Kidney-on-chip
• Liver-on-chip
• Lung-on-chip

Based on type, the lung-on-chip dominated the global organ-on-chip market in 2023 and is predicted to continue the same trend during the forecast period. Lung-on-chip technology is a complicated three-dimensional replica of a living, breathing human lung. This technology, which comprises human lung and blood vessel cells, can predict nanoparticle absorption and stimulate the inflammatory response induced by microbial infections. The device can also assess environmental contaminants, aerosolized treatments absorption, and the safety and efficacy of novel medications. Thus, it is anticipated that it will become a viable alternative to animal testing.

Global Organ-on-chip Market – By Application:

• Drug Discovery
• Toxicology Research
• Other Applications

Drug discovery is expected to be the most popular segment, accounting for the largest share of the global market. As a result, pharmaceutical companies use OOCs widely for drug discovery and clinical trials in various chronic treatment areas.

Global Organ-on-chip Market – By Region:

• North America
• Asia Pacific
• Europe
• Latin America
• The Middle East and Africa

Geographically, North America is predicted to have the most significant share of the global organ-on-chip market and grow at the fastest CAGR. Because of the vast availability of extensive lines of services given by prominent organizations and the spike in chemicals' toxicity testing on various organ cells, America has emerged as the organ-on-chip market leader. In addition, private and public institutes invest a lot of money in extensive research, which adds to the region's market value.

Europe was ranked second worldwide in 2023 and is expected is accelerate at a prominent growth rate. The European market benefits from establishing multiple reputable OOC developers across Germany, the United Kingdom, Italy, Spain, and France, as well as government efforts and financing for research operations. Increased cooperation between corporations, institutes, and universities for the creation of higher-quality OOCs and the availability of well-established healthcare infrastructure are estimated to help the market grow in the next few years.

Due to the lucrative opportunities presented by nations like China, India, and Japan, Asia-Pacific is predicted to develop the fastest over the projection period. Furthermore, as the population's disposable income rises, the region's adoption of Organ-on-a-Chip technology is likely to increase. The expansion of the Organ-on-a-Chip market in the Asia-Pacific region is predicted to be supported by government support for regenerative medicines in research institutions and an increase in the number of cell-based clinical trials and investment in R&D activities.

KEY MARKET PARTICIPANTS:

Emulate, CN Bio Innovations, Tara Biosystems, Draper Laboratory, Mimetas, TissUse, Hesperos, Nortis, Micronit Microtechnologies B.V., Kirkstall, Cherry Biotech SAS, and Else Kooi Laboratory are some of the noteworthy companies operating in the global organ-on-chip market profiled in this report.

RECENT MARKET DEVELOPMENTS:

• CN Bio, a famous creator of innovative single and multi-organ micro physiological systems or organ-on-a-chip, announced the release of their new PhysioMimix OOC Multi-Organ MPS in March 2021.
• In 2020, CN Bio and Imperial College London will collaborate to use CN Bio's liver-on-chip technology to help researchers better understand the underlying mechanisms of alcoholic hepatitis and identify new therapeutic targets.
• The license agreement for InSphero's Akura Flow organ-on-a-chip platform was announced in 2020 by InSphero AG and ETH Bio Engineering Laboratory.